Stockreport

Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal [Seeking Alpha]

Spyre Therapeutics, Inc.  (SYRE) 
PDF Subscribe to Newsletters Sign Up Spyre Therapeutics ( SYRE ) has announced the pricing of an upsized public offering of 6.5M shares of common stock at $62.00 per sh [Read more]